Review



anti-lpar1 antibody  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Alomone Labs anti-lpar1 antibody
    Anti Lpar1 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alr-031/custom%40alr-031%4010%2E1101%2F2025%2E03%2E13%2E643008?v=Alomone+Labs
    Average 93 stars, based on 2 article reviews
    anti-lpar1 antibody - by Bioz Stars, 2026-07
    93/100 stars

    Images



    Similar Products

    anti-lpar1 antibody  (Alomone Labs)
    93
    Alomone Labs anti-lpar1 antibody
    Anti Lpar1 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alr-031/custom%40alr-031%4010%2E1101%2F2025%2E03%2E13%2E643008?v=Alomone+Labs
    Average 93 stars, based on 1 article reviews
    anti-lpar1 antibody - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    lpar1  (Alomone Labs)
    93
    Alomone Labs lpar1
    a. Flow cytometry for <t>LPAR1</t> expression in LM2 CSCs (mCherry pos ) vs nonCSCs (mCherry neg ). b. Quantitation of data in (a). Mean +/− SD, n=3 c. Quantitation of YAP localization in LM2 CSCs vs nonCSCs in unsorted cultures with and without treatment with LPA assessed by immunofluorescent staining (n=524 and 400 for nonCSCs −/+ LPA; n=55 and 80 for CSCs −/+ LPA). Kruskal-Wallis test for CSCs v nonCSCs within treatment group. d. Top 10 enriched transcription factor binding motifs in differentially accessible chromatin regions in sorted LM2 CSCs vs nonCSCs around transcriptional start sites (TSS) or enhancer regions for 2 independent ATAC-Seq experiments. N* = NANOG. (Run 2 only had 9 enriched motifs that were statistically significant.) e. Genes with TEAD binding sites in their enhancers that are preferentially accessible in CSCs. Table shows overlap results of two independent runs (annotated genes only). f. RTQ-PCR for effect of TEAD inhibitor GNE7883 treatment on expression of KLF5 and ID1 in LM2 cells. CTGF is a canonical YAP target as positive control. Results are mean +/− SD for n=3, normalized to vehicle control. Students t-test. g. Flow cytometry for effect of 1D1 or KLF5 knockdown on % CSCs in LM2 cultures. Results are mean +/− SD for n=3, Dunnets multiple comparisons test vs control (CON). h. Schematic for mechanisms underlying hypersensitivity of CSCs to microenvironmental signals.
    Lpar1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alr-031/bio_rxiv__2025__03__13__643008-257-3-4?v=Alomone+Labs
    Average 93 stars, based on 1 article reviews
    lpar1 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    rabbit anti lpar1  (Alomone Labs)
    93
    Alomone Labs rabbit anti lpar1
    a. Flow cytometry for <t>LPAR1</t> expression in LM2 CSCs (mCherry pos ) vs nonCSCs (mCherry neg ). b. Quantitation of data in (a). Mean +/− SD, n=3 c. Quantitation of YAP localization in LM2 CSCs vs nonCSCs in unsorted cultures with and without treatment with LPA assessed by immunofluorescent staining (n=524 and 400 for nonCSCs −/+ LPA; n=55 and 80 for CSCs −/+ LPA). Kruskal-Wallis test for CSCs v nonCSCs within treatment group. d. Top 10 enriched transcription factor binding motifs in differentially accessible chromatin regions in sorted LM2 CSCs vs nonCSCs around transcriptional start sites (TSS) or enhancer regions for 2 independent ATAC-Seq experiments. N* = NANOG. (Run 2 only had 9 enriched motifs that were statistically significant.) e. Genes with TEAD binding sites in their enhancers that are preferentially accessible in CSCs. Table shows overlap results of two independent runs (annotated genes only). f. RTQ-PCR for effect of TEAD inhibitor GNE7883 treatment on expression of KLF5 and ID1 in LM2 cells. CTGF is a canonical YAP target as positive control. Results are mean +/− SD for n=3, normalized to vehicle control. Students t-test. g. Flow cytometry for effect of 1D1 or KLF5 knockdown on % CSCs in LM2 cultures. Results are mean +/− SD for n=3, Dunnets multiple comparisons test vs control (CON). h. Schematic for mechanisms underlying hypersensitivity of CSCs to microenvironmental signals.
    Rabbit Anti Lpar1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alr-031/pm40001482-56-39-43?v=Alomone+Labs
    Average 93 stars, based on 1 article reviews
    rabbit anti lpar1 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    lpa6  (Alomone Labs)
    93
    Alomone Labs lpa6
    a. Flow cytometry for <t>LPAR1</t> expression in LM2 CSCs (mCherry pos ) vs nonCSCs (mCherry neg ). b. Quantitation of data in (a). Mean +/− SD, n=3 c. Quantitation of YAP localization in LM2 CSCs vs nonCSCs in unsorted cultures with and without treatment with LPA assessed by immunofluorescent staining (n=524 and 400 for nonCSCs −/+ LPA; n=55 and 80 for CSCs −/+ LPA). Kruskal-Wallis test for CSCs v nonCSCs within treatment group. d. Top 10 enriched transcription factor binding motifs in differentially accessible chromatin regions in sorted LM2 CSCs vs nonCSCs around transcriptional start sites (TSS) or enhancer regions for 2 independent ATAC-Seq experiments. N* = NANOG. (Run 2 only had 9 enriched motifs that were statistically significant.) e. Genes with TEAD binding sites in their enhancers that are preferentially accessible in CSCs. Table shows overlap results of two independent runs (annotated genes only). f. RTQ-PCR for effect of TEAD inhibitor GNE7883 treatment on expression of KLF5 and ID1 in LM2 cells. CTGF is a canonical YAP target as positive control. Results are mean +/− SD for n=3, normalized to vehicle control. Students t-test. g. Flow cytometry for effect of 1D1 or KLF5 knockdown on % CSCs in LM2 cultures. Results are mean +/− SD for n=3, Dunnets multiple comparisons test vs control (CON). h. Schematic for mechanisms underlying hypersensitivity of CSCs to microenvironmental signals.
    Lpa6, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alr-031/pm35600777-48-5-14?v=Alomone+Labs
    Average 93 stars, based on 1 article reviews
    lpa6 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    anti lpa1  (Alomone Labs)
    93
    Alomone Labs anti lpa1
    a. Flow cytometry for <t>LPAR1</t> expression in LM2 CSCs (mCherry pos ) vs nonCSCs (mCherry neg ). b. Quantitation of data in (a). Mean +/− SD, n=3 c. Quantitation of YAP localization in LM2 CSCs vs nonCSCs in unsorted cultures with and without treatment with LPA assessed by immunofluorescent staining (n=524 and 400 for nonCSCs −/+ LPA; n=55 and 80 for CSCs −/+ LPA). Kruskal-Wallis test for CSCs v nonCSCs within treatment group. d. Top 10 enriched transcription factor binding motifs in differentially accessible chromatin regions in sorted LM2 CSCs vs nonCSCs around transcriptional start sites (TSS) or enhancer regions for 2 independent ATAC-Seq experiments. N* = NANOG. (Run 2 only had 9 enriched motifs that were statistically significant.) e. Genes with TEAD binding sites in their enhancers that are preferentially accessible in CSCs. Table shows overlap results of two independent runs (annotated genes only). f. RTQ-PCR for effect of TEAD inhibitor GNE7883 treatment on expression of KLF5 and ID1 in LM2 cells. CTGF is a canonical YAP target as positive control. Results are mean +/− SD for n=3, normalized to vehicle control. Students t-test. g. Flow cytometry for effect of 1D1 or KLF5 knockdown on % CSCs in LM2 cultures. Results are mean +/− SD for n=3, Dunnets multiple comparisons test vs control (CON). h. Schematic for mechanisms underlying hypersensitivity of CSCs to microenvironmental signals.
    Anti Lpa1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alr-031/pm35600777-68-7-13?v=Alomone+Labs
    Average 93 stars, based on 1 article reviews
    anti lpa1 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    a. Flow cytometry for LPAR1 expression in LM2 CSCs (mCherry pos ) vs nonCSCs (mCherry neg ). b. Quantitation of data in (a). Mean +/− SD, n=3 c. Quantitation of YAP localization in LM2 CSCs vs nonCSCs in unsorted cultures with and without treatment with LPA assessed by immunofluorescent staining (n=524 and 400 for nonCSCs −/+ LPA; n=55 and 80 for CSCs −/+ LPA). Kruskal-Wallis test for CSCs v nonCSCs within treatment group. d. Top 10 enriched transcription factor binding motifs in differentially accessible chromatin regions in sorted LM2 CSCs vs nonCSCs around transcriptional start sites (TSS) or enhancer regions for 2 independent ATAC-Seq experiments. N* = NANOG. (Run 2 only had 9 enriched motifs that were statistically significant.) e. Genes with TEAD binding sites in their enhancers that are preferentially accessible in CSCs. Table shows overlap results of two independent runs (annotated genes only). f. RTQ-PCR for effect of TEAD inhibitor GNE7883 treatment on expression of KLF5 and ID1 in LM2 cells. CTGF is a canonical YAP target as positive control. Results are mean +/− SD for n=3, normalized to vehicle control. Students t-test. g. Flow cytometry for effect of 1D1 or KLF5 knockdown on % CSCs in LM2 cultures. Results are mean +/− SD for n=3, Dunnets multiple comparisons test vs control (CON). h. Schematic for mechanisms underlying hypersensitivity of CSCs to microenvironmental signals.

    Journal: bioRxiv

    Article Title: Hyper-responsiveness of cancer stem cells to microenvironmental cues controls metastasis and therapy response through YAP/TAZ/TEAD

    doi: 10.1101/2025.03.13.643008

    Figure Lengend Snippet: a. Flow cytometry for LPAR1 expression in LM2 CSCs (mCherry pos ) vs nonCSCs (mCherry neg ). b. Quantitation of data in (a). Mean +/− SD, n=3 c. Quantitation of YAP localization in LM2 CSCs vs nonCSCs in unsorted cultures with and without treatment with LPA assessed by immunofluorescent staining (n=524 and 400 for nonCSCs −/+ LPA; n=55 and 80 for CSCs −/+ LPA). Kruskal-Wallis test for CSCs v nonCSCs within treatment group. d. Top 10 enriched transcription factor binding motifs in differentially accessible chromatin regions in sorted LM2 CSCs vs nonCSCs around transcriptional start sites (TSS) or enhancer regions for 2 independent ATAC-Seq experiments. N* = NANOG. (Run 2 only had 9 enriched motifs that were statistically significant.) e. Genes with TEAD binding sites in their enhancers that are preferentially accessible in CSCs. Table shows overlap results of two independent runs (annotated genes only). f. RTQ-PCR for effect of TEAD inhibitor GNE7883 treatment on expression of KLF5 and ID1 in LM2 cells. CTGF is a canonical YAP target as positive control. Results are mean +/− SD for n=3, normalized to vehicle control. Students t-test. g. Flow cytometry for effect of 1D1 or KLF5 knockdown on % CSCs in LM2 cultures. Results are mean +/− SD for n=3, Dunnets multiple comparisons test vs control (CON). h. Schematic for mechanisms underlying hypersensitivity of CSCs to microenvironmental signals.

    Article Snippet: Antibodies used were: LPAR1 (Alomone Labs LTR, Cat# ALR-031).

    Techniques: Flow Cytometry, Expressing, Quantitation Assay, Staining, Binding Assay, Positive Control, Control, Knockdown